nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2D6—Hydroxyurea—head and neck cancer	0.257	0.328	CbGbCtD
Levomilnacipran—CYP2C8—Fluorouracil—head and neck cancer	0.154	0.196	CbGbCtD
Levomilnacipran—ABCB1—Vinblastine—head and neck cancer	0.0966	0.123	CbGbCtD
Levomilnacipran—CYP2D6—Vinblastine—head and neck cancer	0.091	0.116	CbGbCtD
Levomilnacipran—ABCB1—Docetaxel—head and neck cancer	0.0796	0.102	CbGbCtD
Levomilnacipran—CYP3A4—Vinblastine—head and neck cancer	0.0579	0.0738	CbGbCtD
Levomilnacipran—CYP3A4—Docetaxel—head and neck cancer	0.0477	0.0608	CbGbCtD
Levomilnacipran—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00656	0.11	CbGpPWpGaD
Levomilnacipran—Parkinsonism—Fluorouracil—head and neck cancer	0.00547	0.035	CcSEcCtD
Levomilnacipran—CYP2J2—Xenobiotics—CYP1A1—head and neck cancer	0.00315	0.0528	CbGpPWpGaD
Levomilnacipran—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00274	0.0175	CcSEcCtD
Levomilnacipran—Renal failure acute—Hydroxyurea—head and neck cancer	0.00272	0.0174	CcSEcCtD
Levomilnacipran—Angina pectoris—Vinblastine—head and neck cancer	0.00232	0.0148	CcSEcCtD
Levomilnacipran—Breast disorder—Hydroxyurea—head and neck cancer	0.00227	0.0145	CcSEcCtD
Levomilnacipran—Chest discomfort—Docetaxel—head and neck cancer	0.00203	0.013	CcSEcCtD
Levomilnacipran—Dysuria—Hydroxyurea—head and neck cancer	0.00203	0.013	CcSEcCtD
Levomilnacipran—Neutropenia—Hydroxyurea—head and neck cancer	0.00203	0.013	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Vinblastine—head and neck cancer	0.00189	0.0121	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00183	0.0117	CcSEcCtD
Levomilnacipran—Blood pressure increased—Docetaxel—head and neck cancer	0.00179	0.0115	CcSEcCtD
Levomilnacipran—Hallucination—Hydroxyurea—head and neck cancer	0.00173	0.011	CcSEcCtD
Levomilnacipran—Irritability—Fluorouracil—head and neck cancer	0.00172	0.011	CcSEcCtD
Levomilnacipran—Dry skin—Fluorouracil—head and neck cancer	0.00165	0.0106	CcSEcCtD
Levomilnacipran—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00164	0.0274	CbGpPWpGaD
Levomilnacipran—CYP2J2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.00162	0.0271	CbGpPWpGaD
Levomilnacipran—Angiopathy—Hydroxyurea—head and neck cancer	0.00157	0.0101	CcSEcCtD
Levomilnacipran—Chills—Hydroxyurea—head and neck cancer	0.00156	0.00996	CcSEcCtD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00153	0.0256	CbGpPWpGaD
Levomilnacipran—Angina pectoris—Fluorouracil—head and neck cancer	0.00152	0.00972	CcSEcCtD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00151	0.0253	CbGpPWpGaD
Levomilnacipran—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00149	0.0249	CbGpPWpGaD
Levomilnacipran—Leukopenia—Vinblastine—head and neck cancer	0.00148	0.00948	CcSEcCtD
Levomilnacipran—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00146	0.0245	CbGpPWpGaD
Levomilnacipran—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00145	0.00928	CcSEcCtD
Levomilnacipran—Convulsion—Vinblastine—head and neck cancer	0.00143	0.00918	CcSEcCtD
Levomilnacipran—Hypertension—Vinblastine—head and neck cancer	0.00143	0.00915	CcSEcCtD
Levomilnacipran—Hot flush—Docetaxel—head and neck cancer	0.00139	0.00891	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Docetaxel—head and neck cancer	0.00138	0.00883	CcSEcCtD
Levomilnacipran—Urinary tract infection—Fluorouracil—head and neck cancer	0.00135	0.00865	CcSEcCtD
Levomilnacipran—Leukopenia—Hydroxyurea—head and neck cancer	0.00135	0.00865	CcSEcCtD
Levomilnacipran—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00133	0.0223	CbGpPWpGaD
Levomilnacipran—Thrombocytopenia—Vinblastine—head and neck cancer	0.00132	0.00847	CcSEcCtD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00131	0.0219	CbGpPWpGaD
Levomilnacipran—Convulsion—Hydroxyurea—head and neck cancer	0.00131	0.00837	CcSEcCtD
Levomilnacipran—Hyponatraemia—Docetaxel—head and neck cancer	0.00131	0.00837	CcSEcCtD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00129	0.0216	CbGpPWpGaD
Levomilnacipran—Anorexia—Vinblastine—head and neck cancer	0.00129	0.00824	CcSEcCtD
Levomilnacipran—Migraine—Docetaxel—head and neck cancer	0.00128	0.00821	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00128	0.00817	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00124	0.00795	CcSEcCtD
Levomilnacipran—Infection—Hydroxyurea—head and neck cancer	0.00122	0.00783	CcSEcCtD
Levomilnacipran—Paraesthesia—Vinblastine—head and neck cancer	0.00121	0.00777	CcSEcCtD
Levomilnacipran—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00121	0.00773	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00121	0.00772	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—NAT2—head and neck cancer	0.0012	0.0202	CbGpPWpGaD
Levomilnacipran—Liver function test abnormal—Docetaxel—head and neck cancer	0.0012	0.0077	CcSEcCtD
Levomilnacipran—Skin disorder—Hydroxyurea—head and neck cancer	0.0012	0.00766	CcSEcCtD
Levomilnacipran—Dry skin—Docetaxel—head and neck cancer	0.00119	0.00764	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—NAT2—head and neck cancer	0.00119	0.0199	CbGpPWpGaD
Levomilnacipran—Breast disorder—Docetaxel—head and neck cancer	0.00118	0.00753	CcSEcCtD
Levomilnacipran—Anorexia—Hydroxyurea—head and neck cancer	0.00117	0.00752	CcSEcCtD
Levomilnacipran—Decreased appetite—Vinblastine—head and neck cancer	0.00117	0.00752	CcSEcCtD
Levomilnacipran—Constipation—Vinblastine—head and neck cancer	0.00116	0.0074	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00111	0.00707	CcSEcCtD
Levomilnacipran—Dyspnoea—Hydroxyurea—head and neck cancer	0.0011	0.00703	CcSEcCtD
Levomilnacipran—Angina pectoris—Docetaxel—head and neck cancer	0.0011	0.00702	CcSEcCtD
Levomilnacipran—Somnolence—Hydroxyurea—head and neck cancer	0.0011	0.00701	CcSEcCtD
Levomilnacipran—Dyspepsia—Hydroxyurea—head and neck cancer	0.00109	0.00694	CcSEcCtD
Levomilnacipran—Decreased appetite—Hydroxyurea—head and neck cancer	0.00107	0.00686	CcSEcCtD
Levomilnacipran—Abdominal pain—Vinblastine—head and neck cancer	0.00107	0.00684	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00106	0.00681	CcSEcCtD
Levomilnacipran—Fatigue—Hydroxyurea—head and neck cancer	0.00106	0.0068	CcSEcCtD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00106	0.0178	CbGpPWpGaD
Levomilnacipran—Constipation—Hydroxyurea—head and neck cancer	0.00105	0.00674	CcSEcCtD
Levomilnacipran—Neutropenia—Docetaxel—head and neck cancer	0.00105	0.00674	CcSEcCtD
Levomilnacipran—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00103	0.0173	CbGpPWpGaD
Levomilnacipran—Vision blurred—Fluorouracil—head and neck cancer	0.00102	0.00656	CcSEcCtD
Levomilnacipran—Weight decreased—Docetaxel—head and neck cancer	0.00102	0.00652	CcSEcCtD
Levomilnacipran—Hypersensitivity—Vinblastine—head and neck cancer	0.000996	0.00637	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000995	0.00637	CcSEcCtD
Levomilnacipran—Body temperature increased—Hydroxyurea—head and neck cancer	0.000974	0.00623	CcSEcCtD
Levomilnacipran—Leukopenia—Fluorouracil—head and neck cancer	0.000973	0.00623	CcSEcCtD
Levomilnacipran—Asthenia—Vinblastine—head and neck cancer	0.00097	0.0062	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00095	0.00608	CcSEcCtD
Levomilnacipran—Convulsion—Fluorouracil—head and neck cancer	0.000942	0.00603	CcSEcCtD
Levomilnacipran—Chest pain—Fluorouracil—head and neck cancer	0.000926	0.00592	CcSEcCtD
Levomilnacipran—Diarrhoea—Vinblastine—head and neck cancer	0.000925	0.00592	CcSEcCtD
Levomilnacipran—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000908	0.00581	CcSEcCtD
Levomilnacipran—Hepatitis—Docetaxel—head and neck cancer	0.000901	0.00577	CcSEcCtD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000901	0.0151	CbGpPWpGaD
Levomilnacipran—Hypoaesthesia—Docetaxel—head and neck cancer	0.000897	0.00574	CcSEcCtD
Levomilnacipran—Dizziness—Vinblastine—head and neck cancer	0.000894	0.00572	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Docetaxel—head and neck cancer	0.00089	0.0057	CcSEcCtD
Levomilnacipran—Oedema peripheral—Docetaxel—head and neck cancer	0.000888	0.00568	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Docetaxel—head and neck cancer	0.000886	0.00567	CcSEcCtD
Levomilnacipran—Asthenia—Hydroxyurea—head and neck cancer	0.000884	0.00566	CcSEcCtD
Levomilnacipran—Urethral disorder—Docetaxel—head and neck cancer	0.000884	0.00565	CcSEcCtD
Levomilnacipran—Infection—Fluorouracil—head and neck cancer	0.000881	0.00564	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000876	0.0147	CbGpPWpGaD
Levomilnacipran—Nervous system disorder—Fluorouracil—head and neck cancer	0.00087	0.00557	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000869	0.00556	CcSEcCtD
Levomilnacipran—Tachycardia—Fluorouracil—head and neck cancer	0.000866	0.00554	CcSEcCtD
Levomilnacipran—Vomiting—Vinblastine—head and neck cancer	0.000859	0.0055	CcSEcCtD
Levomilnacipran—Erythema multiforme—Docetaxel—head and neck cancer	0.000852	0.00545	CcSEcCtD
Levomilnacipran—Headache—Vinblastine—head and neck cancer	0.000847	0.00542	CcSEcCtD
Levomilnacipran—Anorexia—Fluorouracil—head and neck cancer	0.000846	0.00541	CcSEcCtD
Levomilnacipran—Diarrhoea—Hydroxyurea—head and neck cancer	0.000843	0.0054	CcSEcCtD
Levomilnacipran—Eye disorder—Docetaxel—head and neck cancer	0.000842	0.00539	CcSEcCtD
Levomilnacipran—Flushing—Docetaxel—head and neck cancer	0.000837	0.00535	CcSEcCtD
Levomilnacipran—Cardiac disorder—Docetaxel—head and neck cancer	0.000837	0.00535	CcSEcCtD
Levomilnacipran—Hypotension—Fluorouracil—head and neck cancer	0.000829	0.0053	CcSEcCtD
Levomilnacipran—Angiopathy—Docetaxel—head and neck cancer	0.000818	0.00523	CcSEcCtD
Levomilnacipran—Dizziness—Hydroxyurea—head and neck cancer	0.000815	0.00522	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Docetaxel—head and neck cancer	0.000812	0.0052	CcSEcCtD
Levomilnacipran—Chills—Docetaxel—head and neck cancer	0.000809	0.00517	CcSEcCtD
Levomilnacipran—Nausea—Vinblastine—head and neck cancer	0.000803	0.00514	CcSEcCtD
Levomilnacipran—Insomnia—Fluorouracil—head and neck cancer	0.000802	0.00513	CcSEcCtD
Levomilnacipran—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.0008	0.0134	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Fluorouracil—head and neck cancer	0.000797	0.0051	CcSEcCtD
Levomilnacipran—Dyspnoea—Fluorouracil—head and neck cancer	0.000791	0.00506	CcSEcCtD
Levomilnacipran—Mental disorder—Docetaxel—head and neck cancer	0.00079	0.00505	CcSEcCtD
Levomilnacipran—Somnolence—Fluorouracil—head and neck cancer	0.000789	0.00505	CcSEcCtD
Levomilnacipran—CYP2C8—Xenobiotics—CYP1A1—head and neck cancer	0.000787	0.0132	CbGpPWpGaD
Levomilnacipran—Malnutrition—Docetaxel—head and neck cancer	0.000785	0.00502	CcSEcCtD
Levomilnacipran—Vomiting—Hydroxyurea—head and neck cancer	0.000784	0.00501	CcSEcCtD
Levomilnacipran—Dyspepsia—Fluorouracil—head and neck cancer	0.000781	0.005	CcSEcCtD
Levomilnacipran—Rash—Hydroxyurea—head and neck cancer	0.000777	0.00497	CcSEcCtD
Levomilnacipran—Dermatitis—Hydroxyurea—head and neck cancer	0.000776	0.00497	CcSEcCtD
Levomilnacipran—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000772	0.0129	CbGpPWpGaD
Levomilnacipran—Headache—Hydroxyurea—head and neck cancer	0.000772	0.00494	CcSEcCtD
Levomilnacipran—Decreased appetite—Fluorouracil—head and neck cancer	0.000771	0.00493	CcSEcCtD
Levomilnacipran—Dysgeusia—Docetaxel—head and neck cancer	0.000768	0.00492	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000766	0.0049	CcSEcCtD
Levomilnacipran—CYP2C8—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000757	0.0127	CbGpPWpGaD
Levomilnacipran—Nausea—Hydroxyurea—head and neck cancer	0.000732	0.00468	CcSEcCtD
Levomilnacipran—Urticaria—Fluorouracil—head and neck cancer	0.000705	0.00451	CcSEcCtD
Levomilnacipran—Syncope—Docetaxel—head and neck cancer	0.000704	0.0045	CcSEcCtD
Levomilnacipran—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	0.000703	0.0118	CbGpPWpGaD
Levomilnacipran—Leukopenia—Docetaxel—head and neck cancer	0.000702	0.00449	CcSEcCtD
Levomilnacipran—Body temperature increased—Fluorouracil—head and neck cancer	0.000701	0.00449	CcSEcCtD
Levomilnacipran—Palpitations—Docetaxel—head and neck cancer	0.000693	0.00444	CcSEcCtD
Levomilnacipran—Loss of consciousness—Docetaxel—head and neck cancer	0.00069	0.00441	CcSEcCtD
Levomilnacipran—Convulsion—Docetaxel—head and neck cancer	0.00068	0.00435	CcSEcCtD
Levomilnacipran—Hypertension—Docetaxel—head and neck cancer	0.000677	0.00433	CcSEcCtD
Levomilnacipran—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000676	0.0113	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFA—head and neck cancer	0.00067	0.0112	CbGpPWpGaD
Levomilnacipran—Chest pain—Docetaxel—head and neck cancer	0.000668	0.00427	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000663	0.00424	CcSEcCtD
Levomilnacipran—Hypersensitivity—Fluorouracil—head and neck cancer	0.000654	0.00418	CcSEcCtD
Levomilnacipran—Dry mouth—Docetaxel—head and neck cancer	0.000653	0.00418	CcSEcCtD
Levomilnacipran—CYP2D6—Xenobiotics—CYP1A1—head and neck cancer	0.000646	0.0108	CbGpPWpGaD
Levomilnacipran—Infection—Docetaxel—head and neck cancer	0.000636	0.00407	CcSEcCtD
Levomilnacipran—Shock—Docetaxel—head and neck cancer	0.00063	0.00403	CcSEcCtD
Levomilnacipran—Nervous system disorder—Docetaxel—head and neck cancer	0.000628	0.00402	CcSEcCtD
Levomilnacipran—Pruritus—Fluorouracil—head and neck cancer	0.000628	0.00402	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Docetaxel—head and neck cancer	0.000627	0.00401	CcSEcCtD
Levomilnacipran—Tachycardia—Docetaxel—head and neck cancer	0.000625	0.004	CcSEcCtD
Levomilnacipran—Skin disorder—Docetaxel—head and neck cancer	0.000622	0.00398	CcSEcCtD
Levomilnacipran—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000621	0.0104	CbGpPWpGaD
Levomilnacipran—Anorexia—Docetaxel—head and neck cancer	0.00061	0.00391	CcSEcCtD
Levomilnacipran—Diarrhoea—Fluorouracil—head and neck cancer	0.000607	0.00388	CcSEcCtD
Levomilnacipran—Hypotension—Docetaxel—head and neck cancer	0.000598	0.00383	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—GSTM1—head and neck cancer	0.000595	0.00995	CbGpPWpGaD
Levomilnacipran—Dizziness—Fluorouracil—head and neck cancer	0.000587	0.00375	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GSTM1—head and neck cancer	0.000587	0.00982	CbGpPWpGaD
Levomilnacipran—Insomnia—Docetaxel—head and neck cancer	0.000579	0.00371	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFA—head and neck cancer	0.000576	0.00965	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Docetaxel—head and neck cancer	0.000575	0.00368	CcSEcCtD
Levomilnacipran—Dyspnoea—Docetaxel—head and neck cancer	0.000571	0.00365	CcSEcCtD
Levomilnacipran—Somnolence—Docetaxel—head and neck cancer	0.000569	0.00364	CcSEcCtD
Levomilnacipran—Vomiting—Fluorouracil—head and neck cancer	0.000564	0.00361	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—CYP1A1—head and neck cancer	0.000564	0.00943	CbGpPWpGaD
Levomilnacipran—Dyspepsia—Docetaxel—head and neck cancer	0.000564	0.00361	CcSEcCtD
Levomilnacipran—Rash—Fluorouracil—head and neck cancer	0.000559	0.00358	CcSEcCtD
Levomilnacipran—Dermatitis—Fluorouracil—head and neck cancer	0.000559	0.00358	CcSEcCtD
Levomilnacipran—Decreased appetite—Docetaxel—head and neck cancer	0.000557	0.00356	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000556	0.0093	CbGpPWpGaD
Levomilnacipran—Headache—Fluorouracil—head and neck cancer	0.000556	0.00356	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000553	0.00354	CcSEcCtD
Levomilnacipran—Fatigue—Docetaxel—head and neck cancer	0.000552	0.00353	CcSEcCtD
Levomilnacipran—Constipation—Docetaxel—head and neck cancer	0.000548	0.0035	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00054	0.00903	CbGpPWpGaD
Levomilnacipran—Nausea—Fluorouracil—head and neck cancer	0.000527	0.00337	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000524	0.00335	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000522	0.00873	CbGpPWpGaD
Levomilnacipran—Body temperature increased—Docetaxel—head and neck cancer	0.000506	0.00324	CcSEcCtD
Levomilnacipran—Abdominal pain—Docetaxel—head and neck cancer	0.000506	0.00324	CcSEcCtD
Levomilnacipran—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000505	0.00845	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—UROD—head and neck cancer	0.000496	0.0083	CbGpPWpGaD
Levomilnacipran—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000485	0.00811	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00048	0.00803	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Docetaxel—head and neck cancer	0.000472	0.00302	CcSEcCtD
Levomilnacipran—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00046	0.00769	CbGpPWpGaD
Levomilnacipran—Asthenia—Docetaxel—head and neck cancer	0.000459	0.00294	CcSEcCtD
Levomilnacipran—Pruritus—Docetaxel—head and neck cancer	0.000453	0.0029	CcSEcCtD
Levomilnacipran—Diarrhoea—Docetaxel—head and neck cancer	0.000438	0.0028	CcSEcCtD
Levomilnacipran—Dizziness—Docetaxel—head and neck cancer	0.000423	0.00271	CcSEcCtD
Levomilnacipran—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000422	0.00707	CbGpPWpGaD
Levomilnacipran—Vomiting—Docetaxel—head and neck cancer	0.000407	0.00261	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000406	0.0068	CbGpPWpGaD
Levomilnacipran—Rash—Docetaxel—head and neck cancer	0.000404	0.00258	CcSEcCtD
Levomilnacipran—Dermatitis—Docetaxel—head and neck cancer	0.000403	0.00258	CcSEcCtD
Levomilnacipran—Headache—Docetaxel—head and neck cancer	0.000401	0.00257	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—GSTM1—head and neck cancer	0.000389	0.00652	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000385	0.00644	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000382	0.00639	CbGpPWpGaD
Levomilnacipran—Nausea—Docetaxel—head and neck cancer	0.00038	0.00243	CcSEcCtD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000378	0.00633	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000341	0.00571	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000338	0.00565	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—GSTM1—head and neck cancer	0.000335	0.0056	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000327	0.00547	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000323	0.0054	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TYMS—head and neck cancer	0.000305	0.0051	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—NAT2—head and neck cancer	0.000301	0.00503	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—NAT2—head and neck cancer	0.000296	0.00496	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000292	0.00488	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000288	0.00482	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000275	0.0046	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000268	0.00449	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000268	0.00449	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000265	0.00443	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000265	0.00443	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000265	0.00443	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.000247	0.00413	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.000243	0.00407	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000236	0.00396	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000225	0.00376	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.00022	0.00369	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000219	0.00366	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000218	0.00364	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000217	0.00363	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000216	0.00362	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NAT2—head and neck cancer	0.000206	0.00345	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000201	0.00336	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.0002	0.00335	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—DPYD—head and neck cancer	0.000181	0.00302	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000175	0.00294	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000173	0.0029	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—YAP1—head and neck cancer	0.000171	0.00287	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000167	0.00279	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000164	0.00274	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000161	0.0027	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000159	0.00266	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTM1—head and neck cancer	0.000148	0.00248	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PTEN—head and neck cancer	0.000148	0.00248	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTM1—head and neck cancer	0.000146	0.00245	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000142	0.00238	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP1A1—head and neck cancer	0.000141	0.00236	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000139	0.00232	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	0.000133	0.00222	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	0.000131	0.00219	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000129	0.00215	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2—head and neck cancer	0.000126	0.00211	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	0.000126	0.0021	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000124	0.00207	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—UROD—head and neck cancer	0.000124	0.00207	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000124	0.00207	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	0.000122	0.00204	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000121	0.00202	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.00012	0.00201	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	0.00012	0.00201	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	0.000116	0.00193	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000114	0.00191	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000112	0.00188	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—UROD—head and neck cancer	0.00011	0.00185	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—UROD—head and neck cancer	0.000108	0.0018	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.000107	0.00179	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TYMS—head and neck cancer	0.000103	0.00172	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—head and neck cancer	0.000102	0.0017	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—UROD—head and neck cancer	0.000102	0.0017	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—head and neck cancer	0.000101	0.00169	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GPX1—head and neck cancer	9.74e-05	0.00163	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1A1—head and neck cancer	9.64e-05	0.00161	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	9.6e-05	0.00161	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	8.57e-05	0.00143	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.23e-05	0.00138	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	7.97e-05	0.00133	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.92e-05	0.00133	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	7.89e-05	0.00132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	7.86e-05	0.00132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	7.55e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	7.45e-05	0.00125	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	7.06e-05	0.00118	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.71e-05	0.00112	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UROD—head and neck cancer	6.64e-05	0.00111	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.06e-05	0.00101	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.85e-05	0.000979	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—head and neck cancer	5.73e-05	0.000959	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.46e-05	0.000914	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.4e-05	0.000904	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.28e-05	0.000884	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NAT2—head and neck cancer	5.14e-05	0.00086	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—head and neck cancer	5e-05	0.000837	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	5e-05	0.000836	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.87e-05	0.000815	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.82e-05	0.000807	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.75e-05	0.000796	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.75e-05	0.000795	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NAT2—head and neck cancer	4.59e-05	0.000768	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DPYD—head and neck cancer	4.51e-05	0.000754	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NAT2—head and neck cancer	4.48e-05	0.000749	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—YAP1—head and neck cancer	4.28e-05	0.000716	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NAT2—head and neck cancer	4.22e-05	0.000706	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.13e-05	0.00069	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DPYD—head and neck cancer	4.02e-05	0.000673	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.99e-05	0.000668	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DPYD—head and neck cancer	3.93e-05	0.000657	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—YAP1—head and neck cancer	3.82e-05	0.000639	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—YAP1—head and neck cancer	3.73e-05	0.000624	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DPYD—head and neck cancer	3.7e-05	0.000619	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—head and neck cancer	3.53e-05	0.00059	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—YAP1—head and neck cancer	3.51e-05	0.000588	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.37e-05	0.000564	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.21e-05	0.000538	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—head and neck cancer	2.88e-05	0.000482	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.87e-05	0.00048	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.8e-05	0.000469	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT2—head and neck cancer	2.76e-05	0.000462	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMS—head and neck cancer	2.57e-05	0.00043	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—head and neck cancer	2.54e-05	0.000425	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.5e-05	0.000419	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—head and neck cancer	2.43e-05	0.000407	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DPYD—head and neck cancer	2.42e-05	0.000405	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A1—head and neck cancer	2.41e-05	0.000403	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—YAP1—head and neck cancer	2.3e-05	0.000384	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMS—head and neck cancer	2.29e-05	0.000384	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—head and neck cancer	2.27e-05	0.000379	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMS—head and neck cancer	2.24e-05	0.000374	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—head and neck cancer	2.21e-05	0.00037	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—head and neck cancer	2.17e-05	0.000363	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A1—head and neck cancer	2.15e-05	0.00036	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—head and neck cancer	2.12e-05	0.000354	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMS—head and neck cancer	2.11e-05	0.000353	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.1e-05	0.000351	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—head and neck cancer	2.08e-05	0.000349	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—head and neck cancer	2e-05	0.000334	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.98e-05	0.000331	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.98e-05	0.000331	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.76e-05	0.000295	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—head and neck cancer	1.43e-05	0.00024	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMS—head and neck cancer	1.38e-05	0.000231	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.36e-05	0.000228	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—head and neck cancer	1.3e-05	0.000218	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.29e-05	0.000216	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.28e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—head and neck cancer	1.25e-05	0.000209	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—head and neck cancer	1.25e-05	0.000209	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.18e-05	0.000197	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—head and neck cancer	1.11e-05	0.000186	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—head and neck cancer	1.09e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—head and neck cancer	1.02e-05	0.000171	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—head and neck cancer	8.81e-06	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—head and neck cancer	7.86e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.68e-06	0.000129	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.67e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—head and neck cancer	7.23e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—head and neck cancer	7.19e-06	0.00012	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—head and neck cancer	6.7e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—head and neck cancer	6.42e-06	0.000107	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—head and neck cancer	6.27e-06	0.000105	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—head and neck cancer	5.91e-06	9.88e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.73e-06	7.91e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—head and neck cancer	3.86e-06	6.46e-05	CbGpPWpGaD
